The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition

von Craveiro, Rogerio B, Ehrhardt, Michael, Velz, Julia, Olschewski, Martin, Goetz, Barbara, Pietsch, Torsten, Dilloo, Dagmar
Veröffentlicht in Oncotarget (2017)

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma

von Ehrhardt, Michael, Craveiro, Rogerio B., Velz, Julia, Olschewski, Martin, Casati, Anna, Schönberger, Stefan, Pietsch, Torsten, Dilloo, Dagmar
Veröffentlicht in J Cell Mol Med (2018)